El trastorno por déficit de atención e hiperactividad a lo largo de la vida

  1. Quintero, J. 1
  2. Morales, I. 2
  3. Rodríguez Quiroga, A. 3
  4. Alvarez-Mon Soto, M. 4
  1. 1 Servicio de Psiquiatría, Hospital Universitario Infanta Leonor, Madrid, España Departamento de Medicina Legal y Psiquiatría, Universidad Complutense de Madrid, Madrid, España
  2. 2 Psikids, Madrid, España
  3. 3 Servicio de Psiquiatría, Hospital Universitario Infanta Leonor, Madrid, España
  4. 4 Servicio de Psiquiatría, Hospital Universitario Infanta Leonor, Madrid, España Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá. Alcalá de Henares, Madrid, España
Mostrar afiliaciones +
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Actualidad clínico-terapéutica (II)

Serie: 13

Número: 46

Páginas: 2698-2708

Tipo: Artículo

DOI: 10.1016/J.MED.2021.12.004 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El trastorno por déficit de atención e hiperactividad (TDAH) está catalogado como un trastorno del neurodesarrollo, con prevalencias entre el 2% y el 7%, en función de la etapa de la vida. Se presenta en la infancia, y persiste en la edad adulta hasta en la mitad de los casos, condicionando un factor de riesgo evolutivo, teniendo en la comorbilidad con otros trastornos psiquiátricos prácticamente una constante, siendo los más frecuentes los trastornos de conducta y aprendizaje en la infancia. Mientras que, en la edad adulta, la comorbilidad más prevalente la encontramos con los trastornos afectivos y emocionales. El tratamiento debe partir de un adecuado diagnóstico que trascienda al mero cumplimiento de los criterios diagnósticos, y que se acompañe de un análisis longitudinal de los síntomas, su impacto funcional y comorbilidades. A partir de ahí, la base de un tratamiento multimodal es la pauta de referencia, combinando acciones psicoeducativas, psicofarmacológicas y psicoterapéuticas de manera individualizada.

Referencias bibliográficas

  • Wolraich ML, Chan E, Froehlich T, Lynch RL, Bax A, Redwine ST. ADHD diagnosis and treatment guidelines: A historical perspective. Pediatrics. 2019;144(4):e20191682.
  • Barkley R, Murphy K, Fischer M. Adhd in adults. What the science says. New York: The Guilford Press; 2008.
  • Torgersen T, Gjervan B, Lensing MB, Rasmussen K. Optimal management of ADHD in older adults. Neuropsychiatr Dis Treat [Internet]. 2016;12:79-87.
  • Hodgkins P, Setyawan J, Mitra D, Davis K, Quintero J, Fridman M. Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns. Eur J Pediatr. 2013;172(7):895-906.
  • Cénat JM, Blais Rochette C, Morse C, Vandette MP, Noorishad PG, Kogan C. Prevalence and Risk factors associated with attention deficit/hyperactivity disorder among US black individuals: A systematic review and meta-analysis. JAMA Psychiatry. 2021;78(1):21-8.
  • Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24(4):562-75.
  • Quintero J, Navas M, Fernández A, Ortiz T. Advances in attention deficit hyperactivity disorder.What does neuroimaging provide us with? Actas Esp Psiquiatr. 2009;37(6):352-8.
  • Quintero FJ, Correas J, Quintero FJ. Trastorno por déficit de atención a lo largo de la vida. Barcelona: Masson E; 2010.
  • Reimherr FW, Marchant BK, Gift TE, Steans TA, Wender PH. Revising the diagnostic criteria for Attention Deficit Hyperactivity Disorder (ADHD): an adulthood perspective. Atten Defic Hyperact Disord. 2015;7(2):113-4.
  • Posner J, Polanczyk GV, Sonugabarke E. Attention deficit hyperactivity disorder. 2021;395(10222):450-62.
  • Quintero J, Ramos Quiroga JA, Sebastián JS, Montañés F, Fernández Jaén A, Martínez Raga J. Health care and societal costs of the management of children and adolescents with attention deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry. 2018;18(1):40.
  • Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of attention deficit/hyperactivity disorder in adult patients: a review of the literature. Prim care companion CNS Disord. 2014;16(3):PCC.
  • Wüstner A, Otto C, Schlack R, Hölling H, Klasen F, Ravens Sieberer U. Risk and protective factors for the development of ADHD symptoms in children and adolescents: Results of the longitudinal BELLA study. PLoS One. 2019;14(3):e0214412.
  • Quintero J, Martin M, Alcindor P, Perez Templado J. Prevention in attention deficit hyperactivity disorder. Rev Neurol. 2016;62 Suppl1:S93-7.
  • Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4):e994-1001.
  • Biederman J. Attention deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57(11):1215-20.
  • Polanczyk G, Rohde LA. Epidemiology of attention deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 2007;20(4):386-92.
  • Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr. 2007;166(2):117-23.
  • Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. Am J Psychiatry. 2007;164(6):942-8.
  • Banaschewski T, Becker K, Döpfner M, Holtmann M, Rösler M, Romanos M. Attention deficit/hyperactivity disorder. Dtsch Arztebl Int. 2017;114(9):149-59.
  • Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I. The prevalence of adult attention deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021;11:4009.
  • Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002;5(3):143-54.
  • Antshel KM, Barkley R. Attention deficit hyperactivity disorder. Handb Clin Neurol. 2020;174:37-45.
  • Alexander L, Farrelly N. Attending to adult ADHD: a review of the neurobiology behind adult ADHD. Ir J Psychol Med. 2018; 35(3):237-44.
  • Tistarelli N, Fagnani C, Troianiello M, Stazi MA, Adriani W. The nature and nurture of ADHD and its comorbidities: A narrative review on twin studies. Neurosci Biobehav Rev. 2020 Feb;109:63-77.
  • Khan SA, Faraone S V. The genetics of ADHD: A literature review of 2005. Curr Psychiatry Rep [Internet]. 2006;8(5):393-7.
  • Azeredo A, Moreira D, Barbosa F. ADHD, CD, and ODD: Systematic review of genetic and environmental risk factors. Res Dev Disabil [Internet]. 2018;82:10-9.
  • Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology [Internet]. 2009;57(7):579-89.
  • Kim JH, Kim JY, Lee J, Jeong GH, Lee E, Lee S. Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. The lancet Psychiatry. 2020; 7(11):955-70.
  • Solmi M, Dragioti E, Croatto G, Radua J, Borgwardt S, Carvalho AF. Risk and protective factors for personality disorders: An umbrella review of published meta-analyses of case-control and cohort studies. Front Psychiatry. 2021;12:679379.
  • Elgar FJ, McGrath PJ, Waschbusch DA, Stewart SH, Curtis LJ. Mutual influences on maternal depression and child adjustment problems. Clin Psychol Rev. 2004;24(4):441-59.
  • Chronis AM, Lahey BB, Pelham WEJ, Williams SH, Baumann BL, Kipp H. Maternal depression and early positive parenting predict future conduct problems in young children with attention deficit/hyperactivity disorder. Dev Psychol. 2007;43(1):70-82.
  • Lesesne CA, Visser SN, White CP. Attention deficit/hyperactivity disorder in school aged children: association with maternal mental health and use of health care resources. Pediatrics. 2003;111(5 Pt 2):1232-7.
  • Biederman J, Faraone SV, Monuteaux MC. Differential effect of environmental adversity by gender: Rutter’s index of adversity in a group of boys and girls with and without ADHD. Am J Psychiatry. 2002;159(9):1556-62.
  • Bauermeister JJ, Alegría M, Bird HR, Rubio Stipec M, Canino G. Are attentional hyperactivity deficits unidimensional or multidimensional syndromes? Empirical findings from a community survey. J Am Acad Child Adolesc Psychiatry. 1992;31(3):423-31.
  • Frazier TW, Demaree HA, Youngstrom EA. Meta-analysis of intellectual and neuropsychological test performance in attention deficit/hyperactivity disorder. Neuropsychology. 2004;18(3):543-55.
  • LeRoy A, Jacova C, Young C. Neuropsychological performance patterns of adult ADHD Subtypes. J Atten Disord. 2019;23(10):1136-47.
  • Tsal Y, Shalev L, Mevorach C. The diversity of attention deficits in ADHD: the prevalence of four cognitive factors in ADHD versus controls. J Learn Disabil. 2005;38(2):142-57.
  • Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-65.
  • Christiansen H, Hirsch O, Albrecht B, Chavanon ML. Attention deficit/hyperactivity disorder (ADHD) and emotion regulation over the life span. Curr Psychiatry Rep. 2019;21(3):17.
  • Lenzi F, Cortese S, Harris J, Masi G. Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;84:359-67.
  • Caye A, Swanson J, Thapar A, Sibley M, Arseneault L, Hechtman L. Life span studies of ADHD-conceptual challenges and predictors of persistence and outcome. Curr Psychiatry Rep. 2016;18(12):111.
  • Spencer T, Biederman J, Wilens TE, Faraone SV. Adults with attention deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry. 1998;59Suppl7:59-68.
  • Adler L, Cohen J. Diagnosis and evaluation of adults with attention deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201.
  • Young S, Gudjonsson GH. Growing out of ADHD: the relation-ship between functioning and symptoms. J Atten Disord. 2008;12(2):162-9.
  • Young S, Adamo N, Ásgeirsdóttir BB, Branney P, Beckett M, Colley W. Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. BMC Psychiatry. 2020;20(1):404.
  • Dirks H, Scherbaum N, Kis B, Mette C. [ADHD in adults and comorbid substance use disorder: Prevalence, clinical diagnostics and integrated therapy]. Fortschr Neurol Psychiatr. 2017;85(6):336-44.
  • Quintero J, Morales I, Vera R, Zuluaga P, Fernández A. The impact of adult ADHD in the quality of life profile. J Atten Disord. 2019;23(9):1007-16.
  • Young JL, Goodman DW. Adult attention deficit/hyperactivity disorder diagnosis, management, and treatment in the DSM-5 Era. Prim Care Companion CNS Disord. 2016;18(6).
  • Martínez Núñez B, Quintero J. Update the multimodal treatment of ADHD (MTA): twenty years of lessons. Actas Esp Psiquiatr. 2019;47(1):16-22.
  • Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG. A systematic review and analysis of long term outcomes in attention deficit hyperactivity disorder: effects of treatment and non treatment. BMC Med. 2012;10:99.
  • Salvi V, Migliarese G, Venturi V, Rossi F, Torriero S, Viganò V. ADHD in adults: clinical subtypes and associated characte-ristics. Riv Psichiatr. 2019;54(2):84-9.
  • Gibbins C, Weiss MD, Goodman DW, Hodgkins PS, Landgraf JM, Faraone S V. ADHD-hyperactive/impulsive subtype in adults. 2010;2:41-5.
  • Lee SI, Schachar RJ, Chen SX, Ornstein TJ, Charach A, Barr C. Predictive validity of DSM-IV and ICD-10 criteria for ADHD and hyperkinetic disorder. J Child Psychol Psychiatry. 2008;49(1):70-8.
  • Brown TA, Barlow DH. Dimensional versus categorical classification of mental disorders in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders and beyond: comment on the special section. J Abnorm Psychol. 2005;114(4):551-6.
  • Widiger TA, Samuel DB. Diagnostic categories or dimensions? A question for the Diagnostic And Statistical Manual Of Mental Disorders fifth edition. J Abnorm Psychol. 2005;114(4):494-504.
  • Smyth AC, Meier ST. Evaluating the psychometric properties of the conners adult ADHD rating scales. J Atten Disord. 2019;23(10):1111-8.
  • Ramos Quiroga JA, Chalita PJ, Vidal R, Bosch R, Palomar G, Prats L. Diagnosis and treatment of attention deficit hyperactivity disorder in adults. Rev Neurol. 2012;54Suppl1:S105-15.
  • Reale L, Bartoli B, Cartabia M, Zanetti M, Costantino MA, Canevini MP. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017;26(12):1443-57.
  • McGough JJ, Smalley SL, McCracken JT, Yang M, Del’Homme M, Lynn DE. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry. 2005;162(9):1621-7. Marangoni C, De Chiara L, Faedda GL. Bipolar disorder and ADHD: Comorbidity and diagnostic distinctions. Curr Psychiatry Rep [Internet]. 2015;17(8):67.
  • Wilens TE, Faraone S V, Biederman J, Gunawardene S. Does stimulant therapy of attention deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179-85.
  • Milberger S, Biederman J, Faraone S V, Murphy J, Tsuang MT. Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Am J Psychiatry. 1995;152(12):1793-9.
  • Gómez R, Corr PJ. ADHD and personality: a meta-analytic review. Clin Psychol Rev. 2014;34(5):376-88.
  • Speranza M, Revah Levy A, Cortese S, Falissard B, Pham Scottez A, Corcos M. ADHD in adolescents with borderline personality disorder. BMC Psychiatry. 2011;11:158.
  • Kooij SJJ, Bejerot S, Blackwell A, Caci H, Casas Brugué M, Carpentier PJ. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry [Internet]. 2010;10(1):67.
  • Coghill DR, Caballero B, Sorooshian S, Civil R. A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs. 2014;28(6):497-511.
  • Lichtenstein P, Larsson H. Medication for attention deficit hyperactivity disorder and criminality. N Engl J Med. 2013;368(8):776.
  • Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16(2):131-44.
  • Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Efficacy and Safety of Guanfacine Extended Release in the Treatment of Attention Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double Blind, Placebo Controlled Study. J Clin Psychiatry. 2020;81(3):19m12979.
  • Safren SA. Cognitive behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry. 2006;67Suppl8:46-50.
  • Rubia K, Westwood S, Aggensteiner PM, Brandeis D. Neurotherapeutics for Attention Deficit/Hyperactivity Disorder (ADHD): A review. Cells. 2021;10(8):2156.
Fuente de los datos: Dialnet